XFOR
X4 Pharmaceuticals, Inc. NASDAQ Listed Nov 16, 2017$4.02
+0.75%
vs $3.99
Mkt Cap $170.0M
52w Low $1.42
80.2% of range
52w High $4.66
50d MA $4.08
200d MA $3.78
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.4x
ROE
-42.5%
P/FCF
-1.9x
RSI (14)
56.80
ATR (14)
$0.22
Beta
0.33
50d MA
$4.08
200d MA
$3.78
Avg Volume
767.1K
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
61 North Beacon Street · Boston, MA 02134 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | BMO | -0.36 | -0.22 | +38.9% | 3.56 | +5.3% | +18.8% | -4.3% | +3.0% | +2.6% | -4.9% | — |
| Nov 5, 2025 | BMO | -0.79 | -0.69 | +12.7% | 3.97 | -6.3% | -10.6% | -1.1% | +5.7% | -2.2% | -2.8% | — |
| Aug 8, 2025 | BMO | -4.53 | -3.47 | +23.4% | 1.46 | +2.7% | +2.1% | -4.7% | +81.7% | +13.6% | +7.2% | — |
| May 1, 2025 | BMO | -4.13 | 0.04 | +101.0% | 4.31 | -4.4% | -13.0% | -0.5% | -11.5% | -2.4% | +0.6% | — |
| Mar 25, 2025 | BMO | -5.11 | -6.01 | -17.6% | 8.85 | -3.6% | -12.1% | +3.9% | +0.6% | -7.7% | -5.5% | — |
| Nov 13, 2024 | BMO | -0.17 | -0.18 | -5.9% | 17.76 | -12.6% | -53.2% | +47.8% | -1.5% | -8.3% | -0.5% | — |
| Aug 8, 2024 | BMO | -0.05 | -0.07 | -40.0% | 18.93 | +10.4% | +3.2% | -3.3% | +1.0% | -4.9% | +1.4% | — |
| May 7, 2024 | BMO | -0.17 | -0.26 | -52.9% | 36.00 | -12.5% | -9.2% | -4.6% | +2.9% | -1.9% | -7.0% | — |
| Mar 21, 2024 | BMO | -0.15 | -0.10 | +33.3% | 30.60 | +1.0% | +28.4% | +11.5% | +0.0% | -0.7% | -2.8% | — |
| Nov 9, 2023 | BMO | -0.15 | -0.01 | +93.3% | 22.22 | +1.3% | +6.7% | -5.0% | +1.3% | +4.6% | -1.1% | — |
| Aug 10, 2023 | BMO | -0.17 | -0.33 | -94.1% | 49.20 | -19.5% | -36.0% | +21.9% | -2.3% | -4.0% | -5.0% | — |
| May 4, 2023 | BMO | -0.20 | -0.16 | +20.0% | 44.40 | +1.4% | +4.1% | +10.4% | -4.1% | -6.7% | +5.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2 | Leerink Partners | Initiates | Outperform | $12 | $4.11 | $4.25 | +3.4% | -1.7% | -1.7% | +1.0% | -4.5% | -3.1% |
| Dec 5 | Stifel | Maintains | Buy → Buy | — | $3.80 | $3.94 | +3.7% | +4.7% | -3.5% | -5.2% | +6.9% | -0.3% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.71 | $3.71 | +0.0% | -2.2% | -2.8% | +9.6% | -3.6% | -1.9% |
| Aug 29 | Stifel | Maintains | Buy → Buy | — | $4.12 | $4.01 | -2.7% | -8.7% | -7.7% | -10.1% | +16.7% | -3.8% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.58 | $3.19 | +23.6% | +13.6% | +7.2% | -9.2% | -12.6% | +17.7% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.85 | +2.7% | -0.5% | -11.5% | -2.4% | +0.6% | +1.5% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.08 | $8.10 | +0.2% | +0.6% | -7.7% | -5.5% | -6.2% | +2.9% |
| Mar 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.78 | $7.89 | +1.4% | +3.9% | +0.6% | -7.7% | -5.5% | -6.2% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.50 | $16.67 | +1.0% | -3.8% | -3.8% | -8.0% | +2.6% | +4.6% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.96 | $17.10 | +0.8% | -19.4% | +1.2% | +0.1% | +10.0% | -3.6% |
| Nov 14 | Stifel | Maintains | Buy → Buy | — | $8.32 | $9.15 | +10.0% | +47.8% | -1.5% | -8.3% | -0.5% | -7.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.32 | $9.15 | +10.0% | +47.8% | -1.5% | -8.3% | -0.5% | -7.5% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.10 | $21.00 | +4.5% | -13.4% | +1.6% | -7.6% | +3.7% | -2.7% |
| May 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $29.28 | $29.14 | -0.5% | +3.5% | -1.0% | +8.0% | +0.0% | -5.6% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.70 | $36.00 | +10.1% | +2.8% | -0.9% | -2.7% | +6.5% | +4.3% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.30 | $39.00 | -0.8% | +11.5% | +0.0% | -0.7% | -2.8% | -1.4% |
| Dec 12 | B. Riley Securities | Downgrade | Buy → Neutral | — | $18.18 | $18.00 | -1.0% | +2.6% | +1.4% | +13.1% | +0.2% | -2.4% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.50 | $31.80 | +1.0% | +21.9% | -2.3% | -4.0% | -5.0% | +4.4% |
| May 17 | Stifel | Maintains | Buy → Buy | — | $52.80 | $52.50 | -0.6% | +25.0% | -11.8% | +8.2% | +4.3% | -5.9% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.20 | $47.40 | +2.6% | +10.4% | -4.1% | -6.7% | +5.9% | -7.5% |
| Apr 10 | B. Riley Securities | Maintains | Buy → Buy | — | $24.75 | $24.90 | +0.6% | +5.5% | +9.2% | +20.0% | +7.0% | -5.7% |
| Mar 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.20 | $25.50 | +1.2% | +0.0% | -5.4% | +11.9% | -6.7% | +7.8% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.85 | $26.85 | +0.0% | -4.5% | -1.8% | +0.0% | -5.4% | +11.9% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.85 | $26.85 | +0.0% | -4.5% | -1.8% | +0.0% | -5.4% | +11.9% |
| Dec 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.88 | $25.50 | +6.8% | +5.9% | +2.1% | -10.3% | +9.8% | +10.0% |
| Dec 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.90 | $28.80 | +3.2% | -3.2% | -9.6% | +3.1% | -3.8% | -2.9% |
| Nov 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.50 | $49.20 | -11.4% | -18.9% | -4.0% | -4.2% | -6.5% | -7.0% |
| May 19 | B. Riley Securities | Maintains | Buy → Buy | — | $33.90 | $33.90 | +0.0% | +8.0% | -4.9% | +12.1% | -5.4% | -4.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.20 | $31.80 | +1.9% | +15.4% | +3.3% | -7.3% | -1.7% | +8.0% |
| Apr 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $57.30 | $56.70 | -1.0% | -4.2% | -2.2% | +1.7% | -3.8% | -8.6% |
| Dec 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.20 | $64.50 | +0.5% | -11.2% | +6.3% | +17.3% | +4.2% | -1.6% |
| Dec 17 | Brookline Capital | Maintains | Buy → Buy | — | $183.30 | $187.20 | +2.1% | +6.9% | -1.2% | -0.3% | +2.5% | +6.5% |
| Nov 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $165.90 | $177.30 | +6.9% | +11.8% | +4.7% | +1.2% | +1.2% | -2.9% |
| May 8 | H.C. Wainwright | Maintains | Outperform → Outperform | — | $256.80 | $266.10 | +3.6% | +6.3% | +0.0% | -1.4% | -2.0% | -1.3% |
| May 8 | B. Riley FBR | Maintains | Buy → Buy | — | $256.80 | $266.10 | +3.6% | +6.3% | +0.0% | -1.4% | -2.0% | -1.3% |
| May 8 | B. Riley Securities | Maintains | Buy → Buy | — | $256.80 | $266.10 | +3.6% | +6.3% | +0.0% | -1.4% | -2.0% | -1.3% |
| Mar 26 | Citigroup | Maintains | Buy → Buy | — | $285.00 | $285.30 | +0.1% | -4.3% | -8.7% | +3.0% | +17.0% | -18.3% |
| Mar 13 | B. Riley FBR | Maintains | Buy → Buy | — | $243.90 | $254.70 | +4.4% | -2.8% | -19.4% | +14.8% | -17.5% | +33.7% |
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $243.90 | $254.70 | +4.4% | -2.8% | -19.4% | +14.8% | -17.5% | +33.7% |
| Jan 7 | H.C. Wainwright | Maintains | Buy → Buy | — | $311.70 | $324.60 | +4.1% | +1.3% | -0.9% | -1.0% | +5.7% | -6.5% |
| Dec 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $312.00 | $321.90 | +3.2% | +5.8% | +0.0% | -0.5% | -0.8% | -0.6% |
| Dec 18 | Roth Capital | Maintains | Buy → Buy | — | $330.00 | $330.60 | +0.2% | -1.2% | -1.2% | -3.2% | +5.8% | +0.0% |
| Dec 9 | Citigroup | Upgrade | Neutral → Buy | — | $321.00 | $318.90 | -0.7% | +12.2% | -1.8% | -7.0% | -0.2% | -0.8% |
| Dec 5 | B. Riley | Maintains | Buy → Buy | — | $305.40 | $326.40 | +6.9% | +4.9% | +0.2% | +12.2% | -1.8% | -7.0% |
| May 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $508.80 | $519.60 | +2.1% | +2.6% | -2.1% | +3.6% | -2.7% | +1.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | KIRSKE DAVIDOff | Chief Financial Officer | Sell | 16,961 | $4.29 | $73K | 176,293 | -5.44% | +3.57% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 16,416,030 | $66M | Added | Dec 2025 |
| 2 | Fmr Llc | 8,103,400 | $33M | Reduced | Mar 2026 |
| 3 | Kalehua Capital Management Llc | 3,722,840 | $15M | — | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 3,497,612 | $14M | New | Mar 2026 |
| 5 | Braidwell Lp | 3,368,904 | $13M | New | Dec 2025 |
| 6 | Rosalind Advisors, Inc. | 3,214,766 | $13M | Added | Mar 2026 |
| 7 | Trails Edge Capital Partners, Lp | 2,571,478 | $11M | — | Mar 2026 |
| 8 | Samsara Biocapital, Llc | 1,960,000 | $8M | New | Dec 2025 |
| 9 | Millennium Management | 1,210,514 | $5M | Added | Mar 2026 |
| 10 | Woodline Partners Lp | 1,001,095 | $4M | — | Mar 2026 |
| 11 | Susquehanna International Group, Llp | 856,222 | $4M | Added | Mar 2026 |
| 12 | Stempoint Capital Lp | 850,742 | $4M | New | Mar 2026 |
| 13 | Silverarc Capital Management, Llc | 357,387 | $1M | New | Dec 2025 |
| 14 | Marshall Wace, Llp | 336,834 | $1M | Added | Mar 2026 |
| 15 | Stonepine Capital Management, Llc | 335,309 | $1M | Reduced | Mar 2026 |
| 16 | Ubs Group Ag | 267,340 | $1M | Added | Mar 2026 |
| 17 | Qube Research & Technologies Ltd | 218,954 | $904K | Added | Mar 2026 |
| 18 | Northern Trust Corp | 178,235 | $736K | — | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 150,676 | $622K | Added | Mar 2026 |
| 20 | Palumbo Wealth Management Llc | 131,014 | $541K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 13
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Small Cap Growth Fund | 3,386,200 | $13M | Jan 2026 |
| 2 | Fidelity Small Cap Growth K6 Fund | 1,689,700 | $6M | Jan 2026 |
| 3 | Select Biotechnology Portfolio | 1,685,700 | $6M | Feb 2026 |
| 4 | Fidelity Advisor Biotechnology Fund | 1,341,800 | $5M | Jan 2026 |
| 5 | Fidelity Extended Market Index Fund | 405,184 | $1M | Feb 2026 |
| 6 | Fidelity Total Market Index Fund | 167,464 | $576K | Feb 2026 |
| 7 | Fidelity Series Total Market Index Fund | 139,631 | $480K | Feb 2026 |
| 8 | Schwab Total Stock Market Index Fund | 66,731 | $247K | Jan 2026 |
| 9 | Fidelity Nasdaq Composite Index Fund | 56,741 | $195K | Feb 2026 |
| 10 | Victory Extended Market Index Fund | 8,654 | $32K | Jan 2026 |
| 11 | Knights of Columbus U.S. ALL CAP INDEX FUND | 370 | $1K | Jan 2026 |
| 12 | ProShares UltraPro Russell2000 | 1 | $3 | Feb 2026 |
| 13 | ProShares Russell 2000 High Income ETF | 1 | $3 | Feb 2026 |
Valuation
Market Cap
$170.0M
Enterprise Value
-$6.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.03x
P/B
0.91x
P/S
18.86x
P/FCF
-1.92x
EV/EBITDA
—
Shares Out
42.3M
Financials (TTM)
Revenue
$9.0M
Net Income
-$99.7M
EBITDA
-$89.9M
Free Cash Flow
-$88.6M
Op Cash Flow
-$85.6M
EPS Basic
$-1.87
EPS Diluted
$-4.54
EPS Forward
$-0.87
Gross Margin
79.4%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$290.5M
Total Liab.
$104.2M
Total Equity
$186.3M
Cash
$253.0M
LT Debt
$76.3M
Book Value/Sh
$4.40
Debt/Equity
0.41x
Current Ratio
10.16
Quick Ratio
9.98
Returns & Growth
ROE
-42.5%
ROA
-27.3%
ROIC
-32.7%
Rev Growth YoY
+1273.2%
EPS Growth YoY
+66.5%
Price Returns
2W
+7.8%
1M
+5.9%
3M
+25.3%
6M
+18.4%
12M
+26.8%
Technicals
52W High
$4.66
52W Low
$1.42
50d MA
$4.08
200d MA
$3.78
RSI (14)
56.80
ATR (14)
$0.22
Beta
0.33
Avg Volume
767K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.00
High
$12.00
Low
$10.00
Median
$11.00
Data updated apr 27, 2026 10:30am
· Source: financialmodelingprep.com